Peyronie's Disease
- Updated recommendations on the therapeutic role of extracorporeal shock wave therapy for peyronie's disease: systematic review and meta-analysis. September 18, 2023The therapeutic role of extracorporeal shockwave therapy (ESWT) for Peyronie's disease (PD) has been controversial in a long term. We aimed to further evaluate the therapeutic effect of ESWT for PD on the basis of available high-quality studies.
- European Society of Sexual Medicine consensus statement on the use of animal models for studying Peyronie's disease. September 11, 2023Animal models are frequently used for translational research in Peyronie's disease (PD). However, due to lack of availability of guidelines, there is some heterogeneity in study design, data reporting, and outcome measures.
- Insurance approval rates for collagenase clostridium histolyticum prior to discontinuation: a Canada-wide analysis. September 4, 2023Collagenase Clostridium histolyticum (CCh), the first approved non-surgical treatment for Peyronie's disease (PD), was withdrawn from the European, Canadian, and Asian markets due to poor demand and lack of government reimbursement options.
What Is beyond 9%
Whether you’ve just been diagnosed with Peyronie’s disease or have known for some time, it can be difficult to see beyond the frustrations and limitations that regularly confront you. But rest assured, you’re not alone. In fact, more than 9% of men may develop Peyronie’s. At the APDA, we understand the challenges you’re facing. We’re patients, partners and physicians dealing with it each and every day. And we’re dedicated to helping you go beyond Peyronie’s and back to a more fulfilling life. Learn more
Welcome to APDA
Because the founder of the APDA has Peyronie’s disease, he understands what it’s like. Hear from him and members of the Medical Advisory Board about the organization and its mission to help patients become their own advocates.
If you could help other men with Peyronie’s disease get the help they deserve, would you?
Register for our newsletter!
To help you find answers and better understand this condition, a question-and-answer forum has been developed, where Dr. Laurence Levine and Dr. John Mulhall, along with other members of the APDA Medical Advisory Board and guest contributors, answer questions from patients and their partners. As leaders in Peyronie’s disease research and treatment, board members provide comprehensive and unbiased information about a broad range of topics.
